Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota

Nutrients. 2023 Jan 2;15(1):228. doi: 10.3390/nu15010228.


Dyslipidemia is a multifaceted condition with various genetic and environmental factors contributing to its pathogenesis. Further, this condition represents an important risk factor for its related sequalae including cardiovascular diseases (CVD) such as coronary artery disease (CAD) and stroke. Emerging evidence has shown that gut microbiota and their metabolites can worsen or protect against the development of dyslipidemia. Although there are currently numerous treatment modalities available including lifestyle modification and pharmacologic interventions, there has been promising research on dyslipidemia that involves the benefits of modulating gut microbiota in treating alterations in lipid metabolism. In this review, we examine the relationship between gut microbiota and dyslipidemia, the impact of gut microbiota metabolites on the development of dyslipidemia, and the current research on dietary interventions, prebiotics, probiotics, synbiotics and microbiota transplant as therapeutic modalities in prevention of cardiovascular disease. Overall, understanding the mechanisms by which gut microbiota and their metabolites affect dyslipidemia progression will help develop more precise therapeutic targets to optimize lipid metabolism.

Keywords: Akkermansia muciniphila; Fecalibacterium prausnitszii; fecal microbiota transplantation; folate; mediterranean diet; prebiotics; probiotics; synbiotics.

Publication types

  • Review

MeSH terms

  • Gastrointestinal Microbiome*
  • Microbiota*
  • Prebiotics
  • Probiotics* / therapeutic use
  • Synbiotics*


  • Prebiotics

Grants and funding

This research received no external funding.